tirzepatide glp 1 gip Structures of (a) GLP-1, (b) and (c) [19, 88, 90] Tirzepatide 10mg — GLP-1/GIP Dual-Agonist

Rakhshandehroo, M

Murru A, Sommerhoff C

Tirzepatide may be better if you: Need a medication available right now : Tirzepatide is FDA-approved and available today through clinics and pharmacies Are sensitive to GI side effects : Lower overall side effect rates at every dose level Want established safety data : Years of post-marketing surveillance data available Have insurance coverage : Mounjaro/Zepbound may be partially covered Prefer a simpler titration : Uniform 2.5 mg steps are predictable and easy to follow Are a first-time incretin user : Extensive prescriber experience means better clinical support Retatrutide may be better if you: Have significant fatty liver disease : Liver fat reduction of up to 86% is unmatched Need maximum weight loss : 28.7% at 68 weeks exceeds all other compounds Have plateaued on tirzepatide : The glucagon component offers a new mechanism Are focused on metabolic health beyond weight : Triple agonism impacts more metabolic pathways Can tolerate higher GI burden : More side effects but more results Can wait for FDA approval : Expected late 2026-2027 for regulated access Neither compound is appropriate if you: Have a personal or family history of medullary thyroid carcinoma Have multiple endocrine neoplasia syndrome type 2 Are pregnant or planning pregnancy Have a history of severe psychiatric reactions to incretin therapies Have pancreatitis history (use with extreme caution) For researchers still undecided, the semaglutide vs tirzepatide comparison page provides additional context on how dual agonists compare to single agonists

Patients in the Miami area who continue the typical ultra-processed convenience eating during a cycle leave significant body composition response on the table

Following an extensive review of available data, the EMA's safety committee determined that NAION may affect up to 1 in 10,000 people taking semaglutide for at least one year